

1 **Changes in monocyte subsets can predict the risk of AAA and are surrogate markers**
2 **for AAA morphology in patients with late-stage disease**

3 **Short title:** AAA, monocyte subsets, risk prediction, surrogate marker

4 Bianca Hamann¹, Anna Klimova², Marvin Kapalla¹, David M. Poitz³, Frieda Frank¹,
5 Henning Morawietz⁴, Christian Reeps^{1*} and Anja Hofmann^{1*}

6 *contributed equally

7 ¹Division of Vascular and Endovascular Surgery, Department of Visceral, Thoracic and
8 Vascular Surgery, University Hospital and Medical Faculty Carl Gustav Carus, TUD Dresden
9 University of Technology, Germany;

10 ²Institute for Medical Informatics and Biometry, Faculty of Medicine, TUD Dresden
11 University of Technology, Germany;

12 ³Institute for Clinical Chemistry and Laboratory Medicine; University Hospital and Medical
13 Faculty Carl Gustav Carus, TUD Dresden University of Technology, Germany;

14 ⁴Division of Vascular Endothelium and Microcirculation, Department of Medicine III,
15 University Hospital and Medical Faculty Carl Gustav Carus, TUD Dresden University of
16 Technology, Germany;

17 **#Corresponding author:**

18 Anja Hofmann, PhD

19 Division of Vascular and Endovascular Surgery

20 Department of Visceral-, Thoracic and Vascular Surgery

21 Faculty of Medicine and University Hospital Carl Gustav Carus

22 TUD Dresden University of Technology

23 Fetscherstraße 74

24 D-01307 Dresden, Germany

25 Email: anja.hofmann2@uniklinikum-dresden.de


26

27 **Word count: 3.343 (Excluding references, figure legends and table legends)**

28 **Word count abstract: 217**

29 **NOTE:** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

30 Graphical Abstract



Findings

| | Classical monocytes CD14 ⁺⁺ /CD16 ⁻ | Intermediate monocytes CD14 ⁺⁺ /CD16 ⁺ | Non-classical monocytes CD14 ⁺ /CD16 ⁺⁺ |
|---------------------------|--|---|--|
| | | | |
| Count in peripheral blood | ↓ | ↑ | ↑ |
| AAA risk | ↑ | ↑ | ↑ |
| AAA diameter | — | — | inverse |
| AAA volume | — | — | inverse |
| Intraluminal Thrombus | — | positive | — |

31

32

33

34

35 **Abstract**

36 **Background** Monocytes play a pivotal role in pathology of abdominal aortic aneurysm (AAA)
37 and can display an immunophenotypic heterogeneity with functionally distinct subpopulations.
38 Alterations in monocyte subsets have been described in CVD, and some are associated with
39 cardiovascular risk, but their profile in AAA is poorly understood. **Aim** We aimed to
40 comprehensively define associations of circulating monocyte phenotypes with AAA risk and
41 AAA morphology. **Methods** Monocyte subsets (CD14⁺⁺CD16⁻; CD14⁺⁺/CD16⁺;
42 CD14⁺/CD16⁺⁺) were analyzed in a prospective, observational study in patients with AAA
43 (n=34) and varicose veins (n=34) by using flow cytometry. **Results** Classical monocytes were
44 1.6-fold lower ($P=0.001$) in AAA, while intermediate and non-classical monocytes were 1.8
45 ($P=0.019$) and 1.9-fold ($P=0.025$) higher in AAA, respectively. The differences remained
46 significant after adjusting for age, sex and peripheral artery disease. A lower proportion of
47 classical monocytes (HR: 0.73, $P=0.002$) and increases in intermediate (HR: 1.41, $P=0.006$)
48 and non-classical monocytes (HR: 1.54, $P=0.030$) were associated with a higher risk of AAA.
49 Non-classical monocytes showed an inverse correlation with AAA diameter (Pearson
50 correlation =-0.64, $P=0.001$) and AAA volume (Pearson correlation =-0.50, $P=0.003$).
51 **Conclusion** The present study revealed age- and sex-independent shifts in monocytes, all of
52 which were associated with risk of AAA disease. Non-classical monocytes were inversely
53 correlated with AAA diameter and volume and thus may be surrogate markers for AAA
54 morphology.

55 **Non-standard abbreviations and acronyms**

56 **AAA**, abdominal aortic aneurysm; **ACE**, angiotensin-converting enzyme; **ARBs**, angiotensin
57 receptor blocker; **ASA**, acetylsalicylic acid; **BMI**, body mass index; **CAD**, coronary artery
58 disease; **CAS**, carotid artery stenosis; **CCB**, calcium channel blocker; **CVD**, cardiovascular
59 disease; **Hb**, hemoglobin; **HDL**, high-density lipoprotein cholesterol; **HF**, heart failure; **LDL**,
60 low-density lipoprotein cholesterol; **PAD**, peripheral artery disease; **T2D**, Type 2 diabetes
61 mellitus; **TC**, total cholesterol

62 **What's new?**

- 63 • Classical monocytes are lower in patients with late-stage AAA.
- 64 • Non-classical monocytes showed the strongest increase in AAA disease.
- 65 • A reduction in classical monocytes is associated with increased risk of AAA.
- 66 • An increase in non-classical and intermediate monocytes is associated with an increased
67 risk of AAA.
- 68 • Lowering in non-classical monocytes may be a surrogate marker for AAA morphology,
69 particularly AAA volume.
- 70 • Intermediate monocytes showed a positive correlation with the thickness of the
71 intraluminal thrombus.

72

73 **What are the clinical implications?**

- 74 • The increase in non-classical monocytes could be a novel surrogate marker for AAA
75 volume, which could be useful when AAA diameter is insufficient or to monitor a
76 saccular AAA, as there is a weaker correlation between diameter and risk of rupture in
77 this type of AAA.
- 78 • The decrease in classical monocytes could be a useful surrogate marker for AAA
79 volume and provide additional information on AAA diameter.
- 80 • Monocyte shifts and their association with AAA disease may be relevant for the
81 diagnosis of AAA and should be verified in larger cohorts.
- 82 • The mechanisms behind the decrease in classical monocytes and the increase in
83 intermediate and non-classical subsets should be investigated in further *in vitro* studies
84 as they offer therapeutic potential.

85 **Introduction**

86 Abdominal aortic aneurysm (AAA) is a life-threatening condition with high mortality rates.
87 Main pathological features are inflammation with increased local cytokine production,
88 extracellular matrix degradation, oxidative stress and the loss of smooth muscle cells.¹ The
89 only effective treatment is surgical elimination of the AAA. Pharmacological treatments are
90 still lacking, emphasizing the need to define the pathomechanisms that contribute to the
91 initiation and progression of the disease. Inflammatory cells in AAA comprise monocytes,
92 macrophages, neutrophils, mast cells, natural killer (NK) cells, T and B cells and dendritic
93 cells.² Monocytes are recruited at sites of inflammation where they differentiate into
94 macrophages.³ Monocytes exist in subsets, which differ in morphology, function and cell
95 surface marker (e.g. chemokine receptors) expression. Three distinct subsets were
96 distinguished in humans based on the expression of the the LPS-receptor CD14 and the Fcγ
97 receptor CD16: classical (CD14⁺⁺CD16⁻), non-classical (CD14⁺CD16⁺⁺) and intermediate
98 (CD14⁺⁺CD16⁺) monocytes.⁴ Classical monocytes (CD14⁺⁺CD16⁻) secrete large amounts
99 of pro-inflammatory cytokines and promote angiogenesis, wound healing and coagulation,
100 demonstrating their importance in tissue repair.³ In contrast, CD16-expressing cells may
101 secrete pro-inflammatory cytokines, have a high antigen-presenting capacity and the ability to
102 migrate into subendothelial spaces and atherosclerotic lesions.⁴ These cells include
103 intermediate monocytes (CD14⁺⁺CD16⁺), that secrete pro-inflammatory cytokines and
104 accumulate in chronic inflammatory diseases.^{3,5,6} Intermediate subsets are predictive for
105 cardiovascular disease⁴ and are associated, for example, with susceptibility to plaque
106 vulnerability³. CD16⁺ subsets are elevated in patients with AAA⁷ and a recently published
107 study showed that only intermediate monocytes (CD14⁺⁺CD16⁺) were elevated in AAA
108 compared to healthy individuals and patients with PAD⁸. Interestingly, CD14⁺⁺CD16⁺ and D-

109 dimer proved to be suitable diagnostic markers for AAA while elevated concentrations of these
110 subsets were able to predict rapid growing AAA.⁸

111 Non-classical monocytes have low expression of CD14 (CD14+) and secrete pro- and anti-
112 inflammatory cytokines. These monocytes have phagocytic properties to remove cell debris
113 and are important for patrolling the vascular endothelium and controlling vascular integrity.
114 Most likely, they are involved in the resolution of inflammation.³ However, it should be noted
115 that a CD14-low subset may promote neovascularization and destabilization of lesions, while
116 their accumulation in ischemic tissue may have beneficial effects.⁴

117 Although an increase in intermediate subsets has been demonstrated in AAA, it is still under
118 debate whether the three subgroups correlate with AAA diameter, AAA volume, and thickness
119 of the intraluminal thrombus as the main morphologic features of AAA and could be useful
120 surrogate markers. In addition, there is no information whether any of these monocyte subsets
121 can predict end-stage AAA, when most patients with AAA are diagnosed. Here, we aimed to
122 comprehensively define associations of circulating monocyte phenotypes with AAA risk and
123 AAA morphology.

124 **Materials and Methods**

125 **Study Design**

126 Monocyte subpopulations were determined in an observational study in electively treated AAA
127 patients and patients with varicose veins who served as controls. Due to the observational
128 nature of the study, no sample size or power calculation was performed, according to the
129 STROBE guidelines.⁹ Patients were treated in the Department of Visceral, Thoracic and
130 Vascular Surgery between December 2020 and June 2024. The diagnostic criteria for varicose
131 patients included venous reflux assessed by duplex ultrasound and signs of chronic venous
132 insufficiency according to the CEAP classification.¹⁰ Inclusion criteria were age over 50 years
133 and no known history of arterial disease, T2D and infectious diseases. Patients with
134 thrombophlebitis were excluded. Inclusion criteria for AAA patients were a diameter of the
135 infrarenal aorta of more than 40 mm, a rapidly growing AAA with more than 10 mm
136 progression per year or a symptomatic AAA. The study was approved by the ethics committee
137 of the Technische Universität Dresden (EK 151042017). Informed consent was obtained from
138 all study participants.

139 **Outcome Variables**

140 Counts of each monocyte subset were defined as the primary outcome variable in the
141 multivariate logistic regression, while AAA disease was defined as the outcome variable in the
142 hazard ratio analysis.

143

144 **Clinical Parameters**

145 Serum low-density (LDL) and high-density (HDL) lipoprotein, total cholesterol (TC),
146 triglycerides, non-fasting glucose, hemoglobin (Hb), leukocyte, and C-reactive protein (CRP)
147 concentrations were analyzed in the Institute for Clinical Chemistry and Laboratory Medicine
148 at the TU Dresden using standard laboratory methods. Due to the lack of data on blood

149 chemistry or medical therapies, the number of analyzed patients varies in each group.
150 Cardiovascular risk factors, comorbidities, and prescribed medical therapies were evaluated
151 retrospectively. Hypertension, type 2 diabetes (T2D), heart failure (HF), peripheral artery
152 disease (PAD), and carotid artery stenosis (CAS) were defined by a past documented history
153 of diagnosis or any treatment for these diseases. CAD was defined by a history of myocardial
154 infarction, angina, or treatment for CAD. Smoking was defined as any history of smoking and
155 sex was self-reported.

156

157 **Analysis of AAA Diameter and AAA Morphology**

158 The aortic diameter, maximal intraluminal thrombus depth and aortic volumes were determined
159 as described previously.¹¹ In brief, aortic diameter was assessed by computed tomography
160 angiography by measuring the distance between the outer adventitia (outer-to-outer-edge) by a
161 single trained observer. Thickness of the ILT was determined in the arterial phase on CT scans
162 following multiplanar reconstruction. The aorta was scanned in an axial position in 1 mm
163 sections. The thickness of the ILT was assessed at the largest distance from the inner surface
164 of the lumen to the outer aortic wall. The AAA volume was measured by two trained people
165 using the automatic segmentation model of the IMPAX EE R20 software (Agfa HealthCare,
166 Mortsel, Belgium). The aorta was scanned with contrast media in the arterial phase in 1 mm
167 sections. The outer wall of the aneurysm and the true lumen were selected manually every
168 6 mm in the transverse plane. The starting point of the measurement was defined as the cranial
169 end of the aneurysm with a diameter greater than 30 mm. The measurement ended caudal to
170 the dilation or at the aortic bifurcation. Non-recognized areas were cropped manually. The
171 volume of AAA is given in cm³. The ILT was included in the total AAA volume measurement
172 but was not specifically tagged for segmentation.

173

174 **Blood Samples and Flow Cytometry**

175 Non-fasting venous blood was collected pre-operatively between 2020 and 2024 in 9 mL
176 S-Monovette EDTA (Sarstedt, Nürnberg, Germany). Monocyte subpopulations were
177 analyzed using flow cytometry. Cells were stained for 10 min using the following antibody
178 cocktail: CD45-FITC (HI-30, Thermo Fisher Scientific, Darmstadt, Germany), CD16-
179 PerCP710 (CB16, Thermo Fisher Scientific Darmstadt, Germany) and CD14-PE (M ϕ P9, BD
180 Biosciences, Heidelberg, Germany). Isotype controls were prepared to ensure selectivity of the
181 antibodies. Afterwards, erythrocytes were lysed by the addition of FACS lysing solution (BD
182 Biosciences, Heidelberg, Germany) for 10 min. Data acquisition was performed on LSR
183 Fortessa (BD Biosciences, Heidelberg, Germany) and LSR II (BD Biosciences, Heidelberg,
184 Germany). Data analysis was performed using FlowJoTM Software (Version 10, BD
185 Biosciences, Heidelberg, Germany). First, debris was excluded by applying SSC and FSC, and
186 events with low FSC and SSC signals were omitted. Before cell aggregates were excluded from
187 the analysis, expression of CD45 against the SSC signal was used to select the monocyte
188 population for further analysis. Finally, classical (CD14⁺⁺CD16⁻), non-classical
189 (CD14⁺CD16⁺⁺) and intermediate (CD14⁺⁺CD16⁺) monocytes were determined according
190 to their expression of CD14 and CD16 (**Supplementary Figure 1**).

191

192 **Statistics**

193 Graph Pad Prism 10.0 (GraphPad Software, Inc., La Jolla, CA, USA) and R Core Team (2021)
194 R: A Language and Environment for Statistical Computing software (R Foundation for
195 Statistical Computing, Vienna/Austria) were used for statistical analysis. A *P*-value ≤ 0.05 was
196 considered significant. Outliers were tested with the Grubbs outlier test and normality
197 distribution with the D'Agostino and Pearson test. According to the result of the normal
198 distribution test, Mann–Whitney U or unpaired t-test were used to compare AAA and varicose

199 vein patients. Data are shown as box plots with individual values or as scatter dot plots, as
200 indicated in the figure legends. Correlational analysis was done using Pearson correlation (r_p).
201 Weighted linear regression was performed for variable selection, to assess the influence of age,
202 sex, smoking, hypertension, T2D, CAD, PAD, CRP, HDL-, LDL cholesterol, triglyceride,
203 hemoglobin, leukocyte count, AAA diameter, thickness of the ILT and prescription of insulin,
204 diuretics, statins, ACE, CCB, ARBs, β -blocker, ASA and therapeutic anticoagulation. As some
205 comorbidities strongly influence each other, only age and sex were included in the final
206 analysis. In addition, PAD was included in the multivariate analysis as patients already served
207 as a control group in numerous studies.⁸ Data were analyzed by multivariate logistic regression
208 using each of the monocyte subgroups as a independent variable for the presence of AAA
209 disease. Subgroup concentrations were log transformed, and the effect of risk factors was
210 compared with patients in whom the risk factor was not present.

211 **Results**

212 **Patient Characteristics**

213 The comparison of AAA and venous vein patient's revealed that the AAA group was
214 significantly older and comprised more male patients than varicose vein controls. As expected,
215 both groups differed in their prevalence of cardiovascular risk factors and prescribed
216 pharmacotherapy. A detailed list of risk factors and pharmacotherapy is given in **Table 1**.

217

218 **Phenotypic Heterogeneity of Monocyte Subsets in AAA Patients**

219 In the present study, significant shifts in monocyte subsets were observed in AAA patients
220 compared to controls with varicose veins. In patients with an AAA, there were 1.6-fold lower
221 ($P=0.001$) counts for classical monocytes and 1.9-fold ($P=0.025$) and 1.8-fold ($P=0.019$)
222 higher counts for non-classical monocytes and intermediates, respectively (**Figure 1**). To
223 determine which of the patients' risk factors and comorbidities influenced the subgroups the
224 most, we performed a linear weighted regression. We found that classical monocytes are
225 relatively robust, since they are barely affected by any of the investigated comorbidities and
226 risk factors (**Supplementary Table 1**). In non-classical monocytes, PAD was associated with
227 an increase, and T2D as well as hypertension were associated with a decrease in this subset
228 (**Supplementary Table 2**). Intermediate monocytes were strongly influenced by the presence
229 of T2D, while sex and hypertension were associated with a decrease in this subset
230 (**Supplementary Table 3**). All the investigated comorbidities and risk factors were seen to
231 highly confound each other. We therefore performed a logistic regression analysis and chose
232 age, sex and PAD for adjustment to analyze whether these factors influence the observed
233 differences between varicose veins and AAA. After adjusting for age, sex and PAD the
234 observed decrease in classical monocytes ($P=0.001$) and increase in non-classical monocytes
235 ($P=0.040$) in AAA patients remained significant (**Table 2**).

236 **Monocyte Subsets, AAA Risk and Associations with AAA Morphology**

237 Hazard ratios were calculated to test whether differences in monocyte subgroups lead to an
238 increased risk of AAA disease. A reduced number of classical monocytes was associated with
239 an increased risk of AAA ($P=0.002$). Furthermore, increased levels of non-classical ($P=0.030$)
240 and intermediate monocytes ($P=0.006$) led to a higher risk for AAA disease (**Table 3**).

241

242 **Monocytes and Correlations with AAA Morphology**

243 A correlational analysis was performed to test whether the different monocyte subgroups
244 correlate with the morphology of the AAA and can therefore serve as surrogate markers.
245 Classical monocytes showed a trend to increase with AAA diameter (**Figure 2A**), while no
246 correlations with AAA volume or ILT thickness were found (**Table 4**). Conversely, non-
247 classical monocytes decreased with increasing AAA diameter ($r_p=-0.64$, $P<0.001$) and
248 increasing AAA volume ($r_p=-0.50$, $P=0.003$) (**Figure 2B,C**). Intermediate monocytes showed
249 a trend towards a positive association with maximum depth of the ILT ($r_p=0.32$, $P=0.067$)
250 (**Figure 2D**). **Table 4** provides an extended overview of the tested correlations.

251 Discussion

252 Monocytes are important inflammatory mediators in cardiovascular disease and also in AAA
253 as a particular CVD. Depending on the expression of their surface markers, monocytes are
254 classified into different subgroups that have different functions. Knowledge about their
255 expression patterns may contribute to the understanding of specific disease mechanisms as
256 these cells migrate into inflamed tissue and differentiate into macrophages. Moreover, this
257 would allow the identification of patients at high risk and provide useful surrogate markers for
258 AAA morphology. Although an increase in intermediate subsets has been demonstrated in
259 AAA⁸, nothing is known whether these subsets correlate with AAA diameter, AAA volume
260 and intraluminal thrombus as main morphologic features of AAA. Determination of surrogate
261 markers that correlate with the maximum AAA diameter is of great interest, as the AAA
262 diameter is the most important marker for decisions on surgical therapy.¹² Furthermore, there
263 is no information on whether any of these subgroups can predict the risk of having AAA.
264 The present study showed a lower count of classical monocytes (CD14⁺⁺CD16⁻) and higher
265 counts of intermediate (CD14⁺⁺CD16⁺) and non-classical monocytes (CD14⁺CD16⁺⁺) in
266 patients with AAA. Our data are, at least in part, supported by previously published studies.^{7,8}
267 The decreased proportion of classical monocytes could be explained by findings in mice after
268 induction of acute myocardial infarction. In the first phase, CD14⁺CD16⁻ monocytes
269 accumulate early at the site of injury to clear necrotic debris and promote healing of the
270 damaged tissue. CD14⁺CD16⁺⁺ dominate in the second phase and promote healing through
271 the accumulation of myofibroblasts, angiogenesis and collagen deposition.¹³ The data herein
272 eventually underline an imbalance between both subsets in patients with AAA towards
273 intermediate subsets that promote fibrotic remodeling in the AAA wall. While non-classical
274 monocytes remain in the bloodstream, classical monocytes could transmigrate through the

275 endothelium into the vessel wall.¹⁴ This could be a possible explanation for the depletion of the
276 classic monocytes, which could be due to an increased migration into the AAA.
277 Non-classical monocytes are the most inflammatory subset but also show patrolling function.¹⁵
278 Studies in patients with CAD¹⁶ and subclinical atherosclerosis demonstrated increased non-
279 classical subsets¹⁷ and therefore coincidence the data of the present study. Herein, a higher
280 count of non-classical was found in AAA, which is different to data previously published by
281 Klopff et al.⁸ Most often, patients with PAD served as controls in biomarker studies in AAA.¹⁸
282 PAD is one of the most common initial manifestations of T2D¹⁹ and T2D itself is inversely
283 associated with AAA disease.²⁰ It might be of speculation that a confounding of protective and
284 adverse effects could occur.

285 To further understand the link between AAA risk and blood monocytes, we analyzed whether
286 a specific subtype of monocyte was associated with increased risk of having AAA disease. We
287 were able to show that a lower proportion of classical monocytes was associated with a higher
288 risk of AAA, while an increase in non-classical and intermediate monocytes was associated
289 with an increased risk of AAA. It could be that the increase in intermediate and non-classical
290 subsets occurs at the expense of classical monocytes. Similar results were demonstrated in
291 patients with T2D.²¹ Intermediate monocytes have been demonstrated to be an independent
292 predictor of cardiovascular events in patients with atherosclerotic diseases.²² Similar results
293 were obtained for non-classical monocytes.²² The increased risk might be explained by the
294 proinflammatory role of intermediate and non-classical monocytes.²² Interestingly, the
295 percentage of classical monocytes might be a protective factor for major adverse outcomes in
296 coronary artery disease.²³ Classical monocytes are known to be phagocytic but have no
297 inflammatory potential.¹⁵ Given their protective role, the decrease in AAA and their association
298 with AAA risk might be a hint to a loss of their function.

299 The higher percentage of non-classical, CD14⁺CD16⁺⁺ monocytes was inversely associated
300 with the AAA diameter and AAA volume. Analyzing the AAA volume has the advantage of
301 including the morphology of the aneurysm.²⁴ AAA volume can be useful when the diameter
302 fails or for monitoring saccular AAA, since there is a weaker correlation between increased
303 diameter and rupture risk in this type of AAA.²⁵ Finally, AAA volume might be a better
304 predictor for AAA growth.²⁶ A negative correlation between non-classical, CD14⁺CD16⁺⁺
305 monocytes with the intima-media-thickness was shown in patients with carotid artery stenosis²⁷
306 and in peripheral artery disease where non-classical subsets decreased with the severity⁵.
307 CD14⁺CD16⁺⁺ monocytes (or Ly-6C^{lo} in mice) are involved in healing of the ischemic
308 myocardium and they initiate the differentiation towards M2 macrophages, known to be
309 involved in tissue repair. It might be of speculation, but the inverse relationship could be
310 explained by temporal patterns and lack of their protective and healing functions²⁷, although
311 they are higher in patients with AAA. Another possibility that could explain the inverse
312 relationship between AAA diameter and non-classical monocytes is that non-classical
313 monocytes migrate into the AAA, i.e. as the diameter increases, more cells migrate in and their
314 concentration in the blood decreases. In addition, the patients examined here are in the final
315 stage of the disease and exhibit the typical degeneration of the AAA wall.^{18,28}
316 The majority of AAA are covered by an intraluminal thrombus (ILT). The ILT contains fibrin,
317 inflammatory cells, platelets and red blood cells and affects growth and rupture of the AAA.^{29,30}
318 Herein, intermediate (CD14⁺⁺CD16⁺) subsets tended to correlate with the thickness of the
319 ILT in AAA-patients. Intermediate monocytes are capable of antigen presentation, secreting
320 pro-inflammatory cytokines and to regulate immune responses.³¹ It has been demonstrated that
321 intermediate monocytes are present in the ILT but in lower amounts than in peripheral blood
322 of AAA patients.³² The positive association could reflect the inflammatory nature of the ILT
323 or also cells that are released by the ILT.

324 Overall, the present study showed age- and sex-independent shifts in classical, non-classical
325 and intermediate subsets in AAA, suggesting disease-specific mechanisms. An decrease in
326 classical monocytes and the increases in intermediate and non-classical monocytes were
327 associated with risk for having AAA. The number of non-classical monocytes correlated
328 inversely with AAA diameter and AAA volume and could therefore be a useful surrogate
329 marker for AAA morphology, beyond the AAA diameter. Especially the lowering in
330 phagocytic classical monocytes and the increase in non-classical monocytes should be
331 considered in future studies.

332 **Limitations**


333 The present study is a descriptive, observational study on a very small cohort of patients.
334 Varicose vein patients were used as a control group and their limitation is their different
335 comorbidity and risk factor profile. The relatively small number of patients included and the
336 large number of confounding factors may have influenced the results. Analyzing patients in
337 whom the risk factors have been adjusted prior, e.g. in a case-control study, could minimize
338 these effects. Furthermore, the results obtained here do not allow to establish a causal
339 relationship between the different monocyte subsets and the development of AAA which is due
340 to the study design. Finally, the main discrepancy when comparing data from flow cytometry
341 with the present study is the pre-selection of cells, the declaration of subgroups based on the
342 expression of CD14 and CD16 and the gating strategy in flow cytometry.

343

344 **Acknowledgement**

345 Flow cytometry measurement and analysis was done at the Flow Cytometry Core Facility at
346 TU Dresden, University of Technology. We would like to thank Dr Anne Gompf, Head of the
347 Flow Cytometry Core Facility, for her excellent technical experience.

348 **Figures**



349

350 **Figure 1: Monocyte Subsets in Patients with AAA and Varicose Vein Controls.** Non-

351 fasting venous-blood was collected and the relative frequency of the individual monocyte


352 subpopulations was determined by flow cytometry. **A**, classical (CD14++CD16-), **B**, non-

353 classical (CD14+CD16++) and **C**, intermediate (CD14++CD16+) monocytes. All data are

354 shown as boxplots with individual values. Outliers were identified using the Grubb's outlier

355 test and one patient in each group was excluded from all further analysis. **A**, Unpaired t-test,

356 **B-C**, Mann-Whitney U test.



357

358 **Figure 2: Correlation of Monocyte Subsets and AAA Morphology.** Monocyte subsets were
359 analyzed using flow cytometry and are given as % of total monocytes. The data were
360 logarithmically transformed and analyzed for correlations with the morphology of the AAA.
361 Correlation of **A**, classical monocytes with AAA diameter, **B**, AAA diameter and non-classical
362 monocytes, **C**, non-classical monocytes and AAA volume and **D**, ILT and intermediate
363 monocytes. **Statistics:** Grubb's outlier test was used to identify outliers. One AAA patient was
364 identified as an outlier and excluded from all further analysis. Correlational analysis was done
365 using the Pearson correlation. r_p , Pearson rank correlation coefficient.

366 **Tables**

367 **Table 1: Clinical Characteristics in Patients with Abdominal Aortic Aneurysm (AAA)**

368 **and Venous Vein varicose.** Blood was taken in the non-fasted state. Reference values for the
369 corresponding blood parameters are given in the table. Reference values for LDL and total
370 cholesterol (TC) are based on the European Society of Cardiology (ESC) recommendations.
371 Reference values for fasting glucose were excluded due to the withdrawal in the non-fasted
372 state. **Statistics:** All data are presented as median with minimum and maximum values.
373 Comparison of continuous data was done using the Mann-Whitney U test or t-test. Discrete
374 data were analyzed by Chi-Square test. For t test (a) t-statistic is reported, Mann-Whitney (b)
375 U statistics and Chi-square (c) X^2 is reported. **Abbreviations:** ACE, angiotensin-converting
376 enzyme; ARBs, angiotensin receptor blocker; BMI, body mass index; ASA, acetylsalicylic
377 acid; CAD, coronary artery disease; CCB, calcium channel blocker; HDL, high-density
378 lipoprotein; LDL, low-density lipoprotein; PAD, peripheral artery disease; T2D, type 2
379 diabetes mellitus; TIA, transient ischemic attack.

380

| Observational study | | | | |
|------------------------------|--------------|--------------|---------------------|------------|
| | Varicosis | eAAA | <i>P</i> -value | Statistics |
| Baseline demographics | | | | |
| n included | 33 | 33 | | |
| Age – years, mean ± SD | 62.79 ± 8.15 | 70.39 ± 9.41 | <0.001 ^a | t=3.51 |
| Sex, male:female, % male | 20:13, 61 | 30:3, 91 | 0.0041 ^c | $X^2=8.25$ |

| | | | | |
|--|-----------------------------|-----------------------------|--------------------|----------|
| Hematology | | | | |
| Hemoglobin – mmol/L, mean ± SD, n | 8.99 ± 0.73 32 | 9.01 ± 1.10 33 | 0.948 ^a | t=0.07 |
| Reference values 8.60 – 12.10 mmol/L | | | | |
| Leukocytes – GPt/L, mean ± SD, n | 6.83 ± 1.48 32 | 7.64 ± 1.68 33 | 0.046 ^a | t=2.04 |
| Reference values 3.8 – 9.8 GPt/L | | | | |
| Cardiovascular risk factors | | | | |
| LDL cholesterol – mmol/L, mean ± SD, n | 4.18 ± 1.50 31 | 3.28 ± 1.36 33 | 0.014 ^a | t=2.53 |
| Reference values <1.40 mmol/L for people with very-high risk | | | | |
| HDL cholesterol – mmol/L, median with range, n | 1.63 (1.00 – 2.62) 31 | 1.28 (0.75 – 1.98) 33 | 0.015 ^b | U=331.00 |
| Reference values >0.90 mmol/L for men and >1.10 mmol/L for women | | | | |
| Total cholesterol – mmol/L, mean ± SD, n | 4.57 ± 1.37 31 | 3.52 ± 1.55 33 | 0.006 ^a | t=0.85 |
| Reference values <4.00 mmol/L | | | | |

| | | | | |
|---|------------------------------|------------------------------|---------------------|-----------------------|
| Triglycerides – mmol/L, median with range, n | 1.18 (0.43 – 3.88) 31 | 1.20 (0.52 – 3.59) 32 | 0.582 ^b | U=455.50 |
| Reference values 0.35 – 1.70 mmol/L | | | | |
| Blood glucose – mmol/L, median with range, n | 5.37 (4.30 – 6.81) 28 | 5.94 (4.69 – 11.33) 30 | 0.004 ^b | U=238.50 |
| Reference value only for fasting glucose possible | | | | |
| CRP – mg/L, median with range, n | 1.30 (0.50 – 21.30) 31 | 2.65 (0.60 – 16.80) 31 | 0.049 ^b | U=353.50 |
| Reference values <5.0 mg/L | | | | |
| Smoking, yes:no – % | 6:27, 18 | 23:10, 70 | <0.001 ^c | X ² =17.78 |
| Hypertension, yes:no – % | 11:22, 33 | 30:3, 91 | <0.001 ^c | X ² =23.24 |
| CAD, yes:no – % | 0:33, 0 | 10:23, 30 | 0.001 ^c | X ² =11.79 |
| HF, yes:no – % | 1:32, 3 | 10:23, 30 | 0.003 ^c | X ² =8.84 |
| CAS, yes:no – % | 0:33, 0 | 7:26, 21 | 0.005 ^c | X ² =7.83 |
| PAD, yes:no – % | 0:33, 0 | 8:25, 24 | 0.003 ^c | X ² =9.10 |
| T2D, yes:no – % | 0:33, 0 | 11:22, 33 | <0.001 ^c | X ² =13.20 |

| | | | | |
|--|--------------------------------|--------------------------------|---------------------|-----------------------|
| BMI – kg/m ² , median with range, n | 27.20 (21.20 – 40.70) 33 | 27.25 (20.30 – 38.01) 33 | 0.677 ^b | U=511.50 |
| Pharmacological therapies | | | | |
| Statins, yes:no – % | 3:29, 9 | 24:9, 73 | <0.001 ^c | X ² =26.85 |
| ACE inhibitors, yes:no – % | 3:29, 9 | 15:18, 45 | 0.001 ^c | X ² =10.56 |
| ARB, yes:no – % | 4:28, 13 | 13:20, 39 | 0.014 ^c | X ² =6.08 |
| CCB, yes:no – % | 2:30, 6 | 13:20, 39 | 0.002 ^c | X ² =10.05 |
| ASA, yes:no – % | 2:30, 6 | 25:8, 76 | <0.001 ^c | X ² =32.32 |
| b-blocker, yes:no – % | 4:28, 13 | 17:16, 52 | <0.001 ^c | X ² =11.31 |
| Anticoagulation, yes:no – % | 6:26, 19 | 3:30, 9 | 0.260 ^c | X ² =1.27 |
| Antiplatelet, yes:no – % | 1:31, 3 | 3:30, 9 | 0.317 ^c | X ² =1.00 |
| Diuretics, yes:no – % | 4:28, 13 | 9:24, 27 | 0.137 ^c | X ² =1.49 |
| T2D treatment, yes:no – % | 0:32, 0 | 11:22, 33 | <0.001 ^c | X ² =12.84 |
| Insulin, yes:no – % | 0:32, 0 | 2:31, 6 | 0.157 ^c | X ² =2.00 |

382 **Table 2: Differences in Monocyte Subsets after Adjusting to Age, Sex and PAD.** Monocyte
 383 subsets were analyzed using flow cytometry and monocytes are given in % of total monocytes.
 384 Data were analyzed by multivariate logistic regression using each of the monocyte subgroups
 385 as a diagnostic variable for the presence of AAA disease. The monocyte subgroups were
 386 logarithmically transformed, and data were analyzed by multivariate logistic regression using
 387 the corresponding subset as a predictor variable. The effects of each risk factor were compared
 388 with patients in whom the risk factor was not present (ref=none). The odds ratio (OR) refers to
 389 the relative increase in risk of AAA disease as the percentage of the subgroup increases on the
 390 logarithmic scale. For sex, ORs refer to men and reference values refer to women. AAA
 391 diameter and age show the increase per unit (year and mm, respectively). Unadjusted values
 392 were obtained by pairwise comparison of each variable listed in the table with the outcome of
 393 having an AAA. Adjusted values were analyzed by holding the effects of the other variables
 394 constant and assuming an increase in the monocyte subset on the logarithmic scale.
 395 **Abbreviations:** OR, odds ratio.

396

| Variable | Unadjusted OR [95% CI] | P-value | Adjusted OR [95% CI] | P-value |
|------------------------------------|-----------------------------------|----------------|---------------------------------|----------------|
| classical monocytes [log10] | | | | |
| Group (ref=varicosis) | 0.973 [0.958, 0.987] | <0.001 | 0.968 [0.949, 0.987] | 0.001 |
| Age (years) | 0.999 [0.998, 1.000] | 0.076 | 1.000 [0.999, 1.001] | 0.950 |
| Sex (ref=female) | 1.001 [0.982, 1.021] | 0.895 | 1.014 [0.994, 1.035] | 0.160 |

| | | | | |
|--|----------------------|-------|----------------------|-------|
| PAD (ref=none) | 0.987 [0.963, 1.012] | 0.308 | 1.004 [0.980, 1.029] | 0.754 |
| non-classical monocytes [log10] | | | | |
| Group (ref=varicosis) | 1.504 [1.019, 2.220] | 0.040 | 1.760 [1.058, 2.928] | 0.030 |
| Age (years) | 1.002 [0.981, 1.024] | 0.830 | 0.988 [0.964, 1.012] | 0.331 |
| Sex (ref=female) | 1.024 [0.635, 1.652] | 0.921 | 0.784 [0.462, 1.330] | 0.360 |
| PAD (ref=none) | 1.283 [0.697, 2.360] | 0.417 | 1.026 [0.537, 1.960] | 0.937 |
| intermediate Monocytes [log10] | | | | |
| Group (ref=varicosis) | 1.674 [0.988, 2.836] | 0.055 | 1.940 [0.987, 3.814] | 0.054 |
| Age (years) | 1.024 [0.996, 1.053] | 0.091 | 1.007 [0.975, 1.040] | 0.680 |
| Sex (ref=female) | 0.709 [0.375, 1.343] | 0.287 | 0.563 [0.279, 1.136] | 0.107 |
| PAD (ref=none) | 1.203 [0.527, 2.745] | 0.656 | 0.857 [0.363, 2.024] | 0.721 |

397

398

399 **Table 3: Hazard Ratios of Monocyte Subsets and AAA risk.** Monocyte subsets were
400 analyzed using flow cytometry and monocytes are given in % of total monocytes. Logistic
401 regression was used to obtain hazard ratio of incident AAA per one unit increase in monocytes
402 subsets on log scale.

| | Hazard Ratio [95% CI] | P-value |
|--------------------------------|--|----------------|
| Classical monocytes | 0.726 [0.584, 0.874] | 0.002 |
| Intermediate monocytes | 1.412 [1.123, 1.846] | 0.006 |
| Non-classical monocytes | 1.537 [1.068, 2.354] | 0.030 |

403

404 **Table 4: Summary of Correlations Between Monocyte Subsets and AAA Morphology.**

405 Monocyte subsets were analyzed using flow cytometry and monocyte subsets are given in %
 406 of total monocytes. Data were log transformed. Correlational analysis was performed using
 407 Pearson correlation. Outliers were identified using Grubb’s outlier test and excluded from
 408 further analysis. **Abbreviations:** AAA, Abdominal aortic aneurysm, **ILT**, Intraluminal
 409 thrombus, **r_p**, Pearson’s rank correlation coefficient.

410

| | classical monocytes | | non-classical monocytes | | intermediate monocytes | |
|---------------------|---------------------|---------|-------------------------|------------------|------------------------|--------------|
| | r _p | P-value | r _p | P-value | r _p | P-value |
| AAA diameter | 0.32 | 0.069 | -0.64 | <0.001 | -0.20 | 0.265 |
| ILT | -0.21 | 0.23 | 0.19 | 0.298 | 0.32 | 0.067 |
| AAA volume | 0.27 | 0.13 | -0.50 | 0.003 | -0.13 | 0.481 |

411

412 References

- 413 1. Raffort J, Lareyre F, Clément M, Hassen-Khodja R, Chinetti G, Mallat Z. Monocytes and
414 macrophages in abdominal aortic aneurysm. *Nat Rev Cardiol.* 2017;14:457–471. doi:
415 10.1038/nrcardio.2017.52
- 416 2. Márquez-Sánchez AC, Koltsova EK. Immune and inflammatory mechanisms of
417 abdominal aortic aneurysm. *Front Immunol.* 2022;13:989933. doi:
418 10.3389/fimmu.2022.989933
- 419 3. Ruder AV, Wetzels SMW, Temmerman L, Biessen EAL, Goossens P. Monocyte
420 heterogeneity in cardiovascular disease. *Cardiovasc Res.* 2023;119:2033–2045. doi:
421 10.1093/cvr/cvad069
- 422 4. Hristov M, Leyendecker T, Schuhmann C, Hundelshausen P von, Heussen N, Kehmeier
423 E, Krötz F, Sohn H-Y, Klauss V, Weber C. Circulating monocyte subsets and
424 cardiovascular risk factors in coronary artery disease. *Thromb Haemost.* 2010;104:412–
425 414. doi: 10.1160/TH10-01-0069
- 426 5. Wildgruber M, Aschenbrenner T, Wendorff H, Czubba M, Glinzer A, Haller B,
427 Schiemann M, Zimmermann A, Berger H, Eckstein H-H, Meier R, Wohlgemuth WA,
428 Libby P, Zerneck A. The "Intermediate" CD14⁺⁺CD16⁺ monocyte subset increases in
429 severe peripheral artery disease in humans. *Sci Rep.* 2016;6:39483. doi:
430 10.1038/srep39483
- 431 6. van der Laan AM, Hirsch A, Robbers LFHJ, Nijveldt R, Lommerse I, Delewi R, van der
432 Vleuten PA, Biemond BJ, Zwaginga JJ, van der Giessen WJ, Zijlstra F, van Rossum AC,
433 Voermans C, van der Schoot CE, Piek JJ. A proinflammatory monocyte response is
434 associated with myocardial injury and impaired functional outcome in patients with ST-
435 segment elevation myocardial infarction: monocytes and myocardial infarction. *Am Heart*
436 *J.* 2012;163:57-65.e2. doi: 10.1016/j.ahj.2011.09.002
- 437 7. Ghigliotti G, Barisione C, Garibaldi S, Brunelli C, Palmieri D, Spinella G, Pane B,
438 Spallarossa P, Altieri P, Fabbi P, Sambuceti G, Palombo D. CD16(+) monocyte subsets
439 are increased in large abdominal aortic aneurysms and are differentially related with
440 circulating and cell-associated biochemical and inflammatory biomarkers. *Dis Markers.*
441 2013;34:131–142. doi: 10.1155/2013/836849
- 442 8. Klopff J, Zagraban B, Brandau A, Lechenauer P, Candussi CJ, Rossi P, Celem ND, Ziegler
443 M, Fuchs L, Hayden H, Krenn CG, Eilenberg W, Neumayer C, Brostjan C. Circulating
444 monocyte populations as biomarker for abdominal aortic aneurysms: a single-center
445 retrospective cohort study. *Front Immunol.* 2024;15:1418625. doi:
446 10.3389/fimmu.2024.1418625
- 447 9. Vandenbroucke JP, Elm E von, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, Poole
448 C, Schlesselman JJ, Egger M. Strengthening the Reporting of Observational Studies in
449 Epidemiology (STROBE): explanation and elaboration. *PLoS Med.* 2007;4:e297. doi:
450 10.1371/journal.pmed.0040297
- 451 10. Lurie F, Passman M, Meisner M, Dalsing M, Masuda E, Welch H, Bush RL, Blebea J,
452 Carpentier PH, Maeseneer M de, Gasparis A, Labropoulos N, Marston WA, Rafetto J,
453 Santiago F, Shortell C, Uhl JF, Urbanek T, van Rij A, Eklof B, Glocviczki P, Kistner R,
454 Lawrence P, Moneta G, Padberg F, Perrin M, Wakefield T. The 2020 update of the CEAP
455 classification system and reporting standards. *J Vasc Surg Venous Lymphat Disord.*
456 2020;8:342–352. doi: 10.1016/j.jvsv.2019.12.075
- 457 11. Hamann B, Klimova A, Klotz F, Frank F, Jänichen C, Kapalla M, Sabarstinski P, Wolk S,
458 Morawietz H, Poitz DM, Hofmann A, Reeps C. Regulation of CD163 Receptor in Patients
459 with Abdominal Aortic Aneurysm and Associations with Antioxidant Enzymes HO-1 and
460 NQO1. *Antioxidants (Basel).* 2023;12. doi: 10.3390/antiox12040947

- 461 12. Wanhainen A, Mani K, Golledge J. Surrogate Markers of Abdominal Aortic Aneurysm
462 Progression. *Arterioscler Thromb Vasc Biol.* 2016;36:236–244. doi:
463 10.1161/ATVBAHA.115.306538
- 464 13. Nahrendorf M, Swirski FK, Aikawa E, Stangenberg L, Wurdinger T, Figueiredo J-L,
465 Libby P, Weissleder R, Pittet MJ. The healing myocardium sequentially mobilizes two
466 monocyte subsets with divergent and complementary functions. *J Exp Med.*
467 2007;204:3037–3047. doi: 10.1084/jem.20070885
- 468 14. Feinstein MJ, Doyle MF, Stein JH, Sitlani CM, Fohner AE, Huber SA, Landay AL,
469 Heckbert SR, Rice K, Kronmal RA, Hedrick C, Manichaikul A, McNamara C, Rich S,
470 Tracy RP, Olson NC, Psaty BM, Delaney JAC. Nonclassical Monocytes
471 (CD14dimCD16+) Are Associated With Carotid Intima-Media Thickness Progression for
472 Men but Not Women: The Multi-Ethnic Study of Atherosclerosis-Brief Report.
473 *Arterioscler Thromb Vasc Biol.* 2021;41:1810–1817. doi:
474 10.1161/ATVBAHA.120.315886
- 475 15. Mukherjee R, Kanti Barman P, Kumar Thatoi P, Tripathy R, Kumar Das B, Ravindran B.
476 Non-Classical monocytes display inflammatory features: Validation in Sepsis and
477 Systemic Lupus Erythematosus. *Sci Rep.* 2015;5:13886. doi: 10.1038/srep13886
- 478 16. Urbanski K, Ludew D, Filip G, Filip M, Sagan A, Szczepaniak P, Grudzien G, Sadowski
479 J, Jasiewicz-Honkisz B, Sliwa T, Kapelak B, McGinnigle E, Mikolajczyk T, Guzik TJ.
480 CD14+CD16++ "nonclassical" monocytes are associated with endothelial dysfunction in
481 patients with coronary artery disease. *Thromb Haemost.* 2017;117:971–980. doi:
482 10.1160/TH16-08-0614
- 483 17. Poitou C, Dalmás E, Renovato M, Benhamo V, Hajduch F, Abdennour M, Kahn J-F,
484 Veyrie N, Rizkalla S, Fridman W-H, Sautès-Fridman C, Clément K, Cremer I.
485 CD14dimCD16+ and CD14+CD16+ monocytes in obesity and during weight loss:
486 relationships with fat mass and subclinical atherosclerosis. *Arterioscler Thromb Vasc Biol.*
487 2011;31:2322–2330. doi: 10.1161/ATVBAHA.111.230979
- 488 18. Hofmann A, Khorzom Y, Klimova A, Wolk S, Busch A, Sabarstinski P, Müglichs M,
489 Egorov D, Kopalians I, Poitz DM, Kapalla M, Hamann B, Frank F, Jänichen C, Brunssen
490 C, Morawietz H, Reeps C. Associations of Tissue and Soluble LOX-1 with Human
491 Abdominal Aortic Aneurysm. *J Am Heart Assoc.* 2023;12:e027537. doi:
492 10.1161/JAHA.122.027537
- 493 19. Shah AD, Langenberg C, Rapsomaniki E, Denaxas S, Pujades-Rodriguez M, Gale CP,
494 Deanfield J, Smeeth L, Timmis A, Hemingway H. Type 2 diabetes and incidence of
495 cardiovascular diseases: a cohort study in 1.9 million people. *Lancet Diabetes Endocrinol.*
496 2015;3:105–113. doi: 10.1016/S2213-8587(14)70219-0
- 497 20. Tsai C-L, Lin C-L, Wu Y-Y, Shieh D-C, Sung F-C, Kao C-H. Advanced complicated
498 diabetes mellitus is associated with a reduced risk of thoracic and abdominal aortic
499 aneurysm rupture: a population-based cohort study. *Diabetes Metab Res Rev.*
500 2015;31:190–197. doi: 10.1002/dmrr.2585
- 501 21. Julla J-B, Girard D, Diedisheim M, Saulnier P-J, Tran Vuong B, Blériot C, Carcarino E,
502 Keizer J de, Orliaguet L, Nemazany I, Potier C, Khider K, Tonui DC, Ejlalmanesh T,
503 Ballaire R, Mambu Mambuani H, Germain S, Gaborit B, Vidal-Trécan T, Riveline J-P,
504 Garchon H-J, Fenaille F, Lemoine S, Carlier A, Castelli F, Potier L, Masson D, Roussel
505 R, Vandiedonck C, Hadjadj S, Alzaid F, Gautier J-F, Venteclef N. Blood Monocyte
506 Phenotype Is A Marker of Cardiovascular Risk in Type 2 Diabetes. *Circ Res.*
507 2024;134:189–202. doi: 10.1161/CIRCRESAHA.123.322757
- 508 22. Hristov M, Weber C. Monocyte Subsets in Cardiovascular Disease: A Biomarker
509 Perspective. *Thromb Haemost.* 2024. doi: 10.1055/a-2348-5697

- 510 23. Dregoesc MI, Țigu AB, Bekkering S, van der Heijden CDCC, Rodwell L, Bolboacă SD,
511 Joosten LAB, Netea MG, Riksen NP, Iancu AC. Intermediate monocytes are associated
512 with the first major adverse cardiovascular event in patients with stable coronary artery
513 disease. *Int J Cardiol.* 2024;400:131780. doi: 10.1016/j.ijcard.2024.131780
- 514 24. Kitagawa A, Mastracci TM, Allmen R von, Powell JT. The role of diameter versus volume
515 as the best prognostic measurement of abdominal aortic aneurysms. *J Vasc Surg.*
516 2013;58:258–265. doi: 10.1016/j.jvs.2013.05.001
- 517 25. Vaitėnas G, Mosenko V, Račytė A, Medelis K, Skrebūnas A, Baltrūnas T. Abdominal
518 Aortic Aneurysm Diameter versus Volume: A Systematic Review. *Biomedicines.*
519 2023;11. doi: 10.3390/biomedicines11030941
- 520 26. Lindquist Liljeqvist M, Hultgren R, Gasser TC, Roy J. Volume growth of abdominal aortic
521 aneurysms correlates with baseline volume and increasing finite element analysis-derived
522 rupture risk. *J Vasc Surg.* 2016;63:1434-1442.e3. doi: 10.1016/j.jvs.2015.11.051
- 523 27. Berg KE, Ljungcrantz I, Andersson L, Bryngelsson C, Hedblad B, Fredrikson GN, Nilsson
524 J, Björkbacka H. Elevated CD14++CD16- monocytes predict cardiovascular events. *Circ*
525 *Cardiovasc Genet.* 2012;5:122–131. doi: 10.1161/CIRCGENETICS.111.960385
- 526 28. Hofmann A, Möglich M, Wolk S, Khorzom Y, Sabarstinski P, Kopalians I, Egorov D,
527 Horn F, Brunssen C, Giebe S, Hamann B, Deussen A, Morawietz H, Poitz DM, Reeps C.
528 Induction of Heme Oxygenase-1 Is Linked to the Severity of Disease in Human
529 Abdominal Aortic Aneurysm. *J Am Heart Assoc.* 2021;10:e022747. doi:
530 10.1161/JAHA.121.022747
- 531 29. Koole D, Zandvoort HJA, Schoneveld A, Vink A, Vos JA, van den Hoogen LL, Vries J-
532 PPM de, Pasterkamp G, Moll FL, van Herwaarden JA. Intraluminal abdominal aortic
533 aneurysm thrombus is associated with disruption of wall integrity. *J Vasc Surg.*
534 2013;57:77–83. doi: 10.1016/j.jvs.2012.07.003
- 535 30. Cameron SJ, Russell HM, Owens AP. Antithrombotic therapy in abdominal aortic
536 aneurysm: beneficial or detrimental? *Blood.* 2018;132:2619–2628. doi: 10.1182/blood-
537 2017-08-743237
- 538 31. Williams H, Mack C, Baraz R, Marimuthu R, Naralashetty S, Li S, Medbury H. Monocyte
539 Differentiation and Heterogeneity: Inter-Subset and Interindividual Differences. *Int J Mol*
540 *Sci.* 2023;24. doi: 10.3390/ijms24108757
- 541 32. Sagan A, Mrowiecki W, Mikolajczyk TP, Urbanski K, Siedlinski M, Nosalski R, Korbut
542 R, Guzik TJ. Local inflammation is associated with aortic thrombus formation in
543 abdominal aortic aneurysms. Relationship to clinical risk factors. *Thromb Haemost.*
544 2012;108:812–823. doi: 10.1160/TH12-05-0339
- 545